Cargando…
Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
INTRODUCTION: Ivacaftor has shown to be effective in patients with cystic fibrosis (CF) with a G551D mutation. OBJECTIVES: This work aims to evaluate ivacaftor's effectiveness and safety in the real world, over 5 years, in the West of Scotland CF population. METHODS: We evaluated ivacaftor'...
Autores principales: | Al‐Din, Yasmin, Dryden, Carol, MacGregor, Gordon, Young, David, Coelho, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214567/ https://www.ncbi.nlm.nih.gov/pubmed/36938952 http://dx.doi.org/10.1111/crj.13602 |
Ejemplares similares
-
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Lumacaftor/ivacaftor for cystic fibrosis
Publicado: (2019) -
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022) -
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
por: Higgins, Mark, et al.
Publicado: (2020)